EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population Pharmacokinetics of Casirivimab and Imdevimab in Pediatric and Adult Non-Infected Individuals, Pediatric and Adult Ambulatory or Hospitalized Patients or Household Contacts of Patients Infected with SARS-COV-2

Kuan-Ju Lin, Kenneth C Turner, Maria Rosario, Lutz O Harnisch, John D Davis, A Thomas DiCioccio

Pharmaceutical Research · 2024

DOI: 10.1007/s11095-024-03764-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von Kuan-Ju Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA. kuanju.lin@regeneron.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, COVID-19 Drug Treatment, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biomedical Advanced Research and Development Authority, Regeneron Pharmaceuticals, F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Casirivimab (CAS) and imdevimab (IMD) are two fully human monoclonal antibodies that bind different epitopes on the receptor binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and block host receptor interactions. CAS + IMD and was developed for the treatment and prevention of SARS-CoV-2 infections.

Methods

A population pharmacokinetic (PopPK) analysis was conducted using pooled data from 7598 individuals from seven clinical studies to simultaneously fit concentration–time data of CAS and IMD and investigate selected covariates as sources of variability in PK parameters. The dataset comprised CAS + IMD-treated pediatric and adult non-infected individuals, ambulatory or hospitalized patients infected with SARS-CoV-2, or household contacts of patients infected with SARS-CoV-2.

Results

CAS and IMD concentration–time data were both appropriately described simultaneously by a two-compartment model with first-order absorption following subcutaneous dose administration and first-order elimination. Clearance estimates of CAS and IMD were 0.193 and 0.236 L/day, respectively. Central volume of distribution estimates were 3.92 and 3.82 L, respectively. Among the covariates identified as significant, body weight and serum albumin had the largest impact (20–34%, and ~ 7–31% change in exposures at extremes, respectively), while all other covariates resulted in small differences in exposures. Application of the PopPK model included simulations to support dose recommendations in pediatrics based on comparable exposures of CAS and IMD between different weight groups in pediatrics and adults following weight-based dosing regimens.

Conclusions

This analysis provided important insights to characterize CAS and IMD PK simultaneously in a diverse patient population and informed pediatric dose selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCOVID-19 Drug TreatmentSARS-CoV-2COVID-19HumansChildAdultAdolescentMaleFemaleMiddle AgedChild, PreschoolYoung AdultInfantAgedHospitalizationModels, BiologicalAntiviral AgentsAntibodies, Monoclonal

Stichwörter der Autor:innen

COVID-19Monoclonal antibodyPharmacodynamicsPharmacokinetics

Substanzen

Antibodies, Monoclonal, HumanizedcasirivimabimdevimabAntiviral AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA. kuanju.lin@regeneron.com.
  • Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA.

Förderung

  • Biomedical Advanced Research and Development Authority
  • Regeneron Pharmaceuticals
  • F. Hoffmann-La Roche
  • U.S. Department of Health and Human Services
  • Administration for Strategic Preparedness and Response

Zitieren

APA

Lin, K. J., Turner, K. C., Rosario, M., Harnisch, L. O., Davis, J. D., & DiCioccio, A. T. (2024). Population Pharmacokinetics of Casirivimab and Imdevimab in Pediatric and Adult Non-Infected Individuals, Pediatric and Adult Ambulatory or Hospitalized Patients or Household Contacts of Patients Infected with SARS-COV-2. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03764-5

Vancouver

Lin KJ, Turner KC, Rosario M, Harnisch LO, Davis JD, DiCioccio AT. Population Pharmacokinetics of Casirivimab and Imdevimab in Pediatric and Adult Non-Infected Individuals, Pediatric and Adult Ambulatory or Hospitalized Patients or Household Contacts of Patients Infected with SARS-COV-2. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03764-5

BibTeX
@article{Lin2024,
  author = {Lin, Kuan-Ju and Turner, Kenneth C and Rosario, Maria and Harnisch, Lutz O and Davis, John D and DiCioccio, A Thomas},
  title = {Population Pharmacokinetics of Casirivimab and Imdevimab in Pediatric and Adult Non-Infected Individuals, Pediatric and Adult Ambulatory or Hospitalized Patients or Household Contacts of Patients Infected with SARS-COV-2},
  journal = {Pharmaceutical Research},
  year = {2024},
  doi = {10.1007/s11095-024-03764-5}
}
Kostenlos starten →